Leerink Partners analyst David Risinger has reiterated their bullish stance on CNTA stock, giving a Buy rating on July 14.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
David Risinger has given his Buy rating due to a combination of factors that suggest a promising outlook for Centessa Pharmaceuticals. One key reason is the potential differentiation of CNTA’s ORX750 in terms of efficacy and safety compared to its competitor’s product, alixorexton. The recent results from ALKS’s trial of alixorexton in narcolepsy type 1 (NT1) patients validate the orexin agonist class, which includes ORX750, and suggest that ORX750 might offer unique benefits.
Moreover, while alixorexton showed some positive results, there were areas where ORX750 could potentially outperform, particularly in safety and efficacy. The management of CNTA remains optimistic about ORX750’s distinct profile, and upcoming Phase 2a trial results could further support this view. These factors combined with the broader positive perception of the orexin agonist class contribute to Risinger’s Buy rating for CNTA.
In another report released on July 14, BMO Capital also maintained a Buy rating on the stock with a $35.00 price target.
CNTA’s price has also changed slightly for the past six months – from $16.460 to $16.060, which is a -2.43% drop .